Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
C8 Glucosyl(β) Ceramide (d18:1/8:0) or D-glucosyl-β-1,1′-N-octanoyl-D-erythro-sphingosine has been used as a stock solution for the in vitro treatment of bacteria and to study the role of sphingolipids on pulmonary Pseudomonas aeruginosa infections in cystic fibrosis (CF). It may be suitable for the preparation ofliposomes. It may also be used as a standard for the quantification of mitoxantrone in tumor by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Biochem/physiol Actions
C8 Glucosyl(β) Ceramide (d18:1/8:0) or D-glucosyl-β-1,1′-N-octanoyl-D-erythro-sphingosine improves intracellular drug delivery in tumor cells. It is also considered as a drug uptake enhancer.
General description
C8 Glucosyl(β) Ceramide (d18:1/8:0) or D-glucosyl-β-1,1′-N-octanoyl-D-erythro-sphingosine is a short-chain glycosphingolipid (SC-GSL).
Packaging
5 mL Amber Glass Screw Cap Vial (860540P-5mg)
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :